Global Point Of Care Lipid Test Market size is expected to reach USD 280.02 million by 2022 according to a new report by Grand View Research Inc. Growing geriatric population base, increasing global prevalence of cardiovascular diseases, and rising healthcare awareness due to patient education are the driving forces for the PoC Lipid Test industry growth during the forecast period.
Furthermore,
continuous efforts by the government to reduce hospital stays and curb
healthcare expenditure, establishments attempting to provide effective and
rapid diagnostic results, and improvement in technology with the provision of
cheap and high-quality medical solutions aimed at achieving lab automation are
some factors contributing to the growth of the PoC Lipid Test market.
Request
a sample copy or view summary of this report @
http://www.grandviewresearch.com/industry-analysis/point-of-care-poc-lipid-test-market
Further key findings from the study suggest:
- Alere
Cholestech LDx market was estimated at over 6,400 units in 2014 and is
expected to reach over 11,000 units by 2022, growing at a CAGR of 7.8%
over the forecast period. The analyzer is included in the CLIA waived test
list and is certified by the Cholesterol Reference Method Laboratory
Method Network (CRMLN) program and Lipid Standardization Program (LSP)
- Global
launch of Roche Cobas b 101 at the end of 2013 excluding the U.S. region
and the introduction of Samsung LABGEO PT10 in the Indian market are
expected to drive the point of care Lipid Test market at a lucrative rate
over the next six years
- Consumables
Piccolo Express by Abaxis market was valued over 1,000 thousand units in
2014 owing to the presence of CLIA-waived capillary or venous lipid and
liver panel used for monitoring statin medications results. Abaxis is the
only company, which provides a venous or capillary or CLIA waived Lipid
and Liver panel.
- Hyperlipidemia
is the largest application area for PoC Lipid Test industry with revenue
of over USD 55 million in 2014. Whereas, hypertriglyceridemia is the
fastest growing application area with the expected growth rate of 5.6%
during the forecast period due to increasing incidences of
hypertriglyceridemia and the introduction of technologically advanced
products such as CardioChek PA by PTS Diagnostics.
- Europe
constituted the largest share of over 35% in 2014 of the total market.
Presence of favorable regulations and initiatives pertaining to the
development of healthcare infrastructure, and also high disease prevalence
levels in the region are the major factors responsible for its growth
- Asia Pacific
accounted for over 19% share in 2014 of the total market. However, the
market share of this region is estimated to increase at a CAGR of 5.8% by
2022 due to increasing demand for rapid diagnostic testing in developing
countries such as India and China.
- Some key
players of this market include Abaxis Inc., Roche Diagnostics, Alere Inc.,
Polymer Technology Systems (PTS Diagnostics), and Samsung Electronics
Corporation. Alere with its product portfolio including Alere Cholestech
LDx and Alere Afinion AS100 Analyzer was the leader in the POC lipid
testing market with a share of over 22% in 2014.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment